New Tysabri data presented at AAN Meeting

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

New Tysabri data presented at AAN Meeting

Postby MSUK » Thu Apr 26, 2012 11:37 pm

Image


Biogen Idec and Elan Corporation announced findings from several studies of Tysabri(R) (natalizumab) evaluating its long-term safety and efficacy in the treatment of multiple sclerosis (MS) across the course of disease and impact on MS-related symptoms such as fatigue. These data, as well as data relating to the companies' risk stratification algorithm as a way to help enable individual benefit risk assessment for patients with MS, were accepted for presentation at the 64th Annual Meeting of the American Academy of Neurology (AAN).

"We continue to build on the extensive data we have for Tysabri and are committed to studying its long-term use and potential effect on symptoms like fatigue, which MS patients struggle with every day," said Douglas E. Williams, Ph.D., executive vice president of Research and Development at Biogen Idec. "Our research is aimed at discovering additional ways Tysabri can help physicians and patients best manage the symptoms of MS and make informed and personalized treatment choices."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2225
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service